A61K 40/427
Prame
Official title: {prame}
A61K40/427 (Prame) appears on 29 US grants and 95 published applications in this corpus.
Search patents in A61K- Granted patents
- 29
- Published applications
- 95
- Assignees
- 33
- Inventors
- 156
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 0 | 2 |
| 2015 | 0 | 1 |
| 2016 | 1 | 4 |
| 2017 | 0 | 1 |
| 2018 | 2 | 1 |
| 2019 | 2 | 6 |
| 2020 | 2 | 10 |
| 2021 | 3 | 6 |
| 2022 | 2 | 15 |
| 2023 | 3 | 19 |
| 2024 | 3 | 11 |
| 2025 | 6 | 7 |
| 2026 | 4 | 8 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- PRAME TCR receptors and uses thereof19 May 2026US 12,630,607 B2BioNTech SE
- Targeted T-cell therapy for treatment of multiple myeloma31 Mar 2026US 12,590,292 B2Children's National Medical Center
- Biomaterial-based antigen free vaccine and the use thereof6 Jan 2026US 12,514,865 B2President and Fellows of Harvard College
- Compositions and methods for adoptive cell therapy16 Dec 2025US 12,496,310 B2Memorial Sloan Kettering Cancer Center
- Nucleic acid molecule encoding a car and a vector including the same, a car, an immune cell including the car and a pharmaceutical composition including the cell, and a method for producing an immune cell including the car30 Jul 2026US 2026/0217856 A1Mie University
- Immune cell engineered with il-8 receptor and use thereof7 May 2026US 2026/0124301 A1Children's National Medical Center
- Compositions and methods for adoptive cell therapy for cancer23 Apr 2026US 2026/0109675 A1Memorial Sloan Kettering Cancer Center
- Compositions and methods for adoptive cell therapy for cancer16 Apr 2026US 2026/0103696 A1Memorial Sloan Kettering Cancer Center
- Combination of ny-eso-1 specific t cell receptors and chimeric co-stimulatory receptors26 Feb 2026US 2026/0055159 A1Medigene Immunotherapies GmbH
Most cited
By later US patents
- PRAME derived peptides and immunogenic compositions comprising these11US 10,450,356 B2Academisch Ziekenhuis Leiden (H.O.D.N. Lumc) · 2019
- Generation of broadly-specific, virus-immune cells targeting multiple HIV antigens for preventive and therapeutic use11US 9,885,021 B2Children's National Medical Center · 2018
- Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses10US 9,963,677 B2Baylor College of Medicine · 2018
- Reversing the effects of the tumor microenvironment using chimeric cytokine receptors8US 10,548,921 B2Baylor College of Medicine · 2020
- Generation of CTL lines with specificity against multiple tumor antigens or multiple viruses4US 10,385,316 B2Baylor College of Medicine · 2019